Last reviewed · How we verify
PT20
At a glance
| Generic name | PT20 |
|---|---|
| Also known as | Iron (III) oxide adipate, ferric oxide adipate, iron (III) oxide hydroxide adipate, M10L78 |
| Sponsor | Phosphate Therapeutics |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Gait and Paraspinal sEMG in Degenerative Spinal Diseases
- Dual Task Training With Vestibular Stimulation in Children With Diplegic Cerebral Palsy (NA)
- Serious Games for Serious Outcomes: Enhancing Cognition, Balance, and Quality of Life in Children With Cerebral Palsy (NA)
- Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PT20 CI brief — competitive landscape report
- PT20 updates RSS · CI watch RSS
- Phosphate Therapeutics portfolio CI